


Clinical

Analysis of 25-Hydroxyvitamin D₂ and D₃ in Serum Using UHPLC/SQ MS



Vitamin D (where D refers to D₂ or D₃) is a fat-soluble pro-hormone that when metabolized into its active form targets less than 200 human genes in a wide variety of tissues in the body. In addition to the major physiological function of vitamin D metabolites to maintain calcium and phosphate homeostasis, vitamin D status has been associated with a variety of disease states including cancer, cardiovascular disease, diabetes, multiple sclerosis, osteoporosis, rheumatoid arthritis, and chronic pain.

Vitamin D₃ (cholecalciferol) is formed in the skin upon exposure to sunlight and vitamin D₂ (ergocalciferol) is obtained from the ultraviolet irradiation of plant materials (Figure 1). Natural sources of vitamin D₃ include oily fish (such as salmon or mackerel), cod liver oil, and fortified food (such as milk, orange juice, butter, cheeses, and breakfast cereals). Prescription vitamin D preparations contain ergocalciferol (50,000 IU/capsule) while over-the-counter supplements contain cholecalciferol (400, 800, 1000, and 2000 IU/capsule).




Figure 1. Structures of Vitamin D₂ (ergocalciferol) and Vitamin D₃ (cholecalciferol).




Figure 2. Formed in the skin, vitamins D₃ and D₂ are converted into their metabolically active forms by subsequent reactions in the liver and kidneys.

Upon penetration of the skin with ultraviolet B radiation, vitamin D₃ is synthesized from 7-dehydrocholesterol to form previtamin D₃ which is rapidly converted by a thermally-induced process to vitamin D₃. Vitamin D₃ is converted into its metabolically active form 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) by two subsequent hydroxylations, consisting of 25-hydroxylation in the liver followed by 1 α -hydroxylation in the kidney (Figure 2). Both hydroxylations are carried out by specific cytochrome P450-containing enzymes, the first by vitamin D 25-hydroxylase (CYP27) and the second by 25-hydroxyvitamin D 1 α -hydroxylase (CYP1 α).

25-Hydroxyvitamin D is the metabolite measured in the blood to determine the vitamin D status of patients. Methodologies for measuring serum 25(OH)D include competitive protein binding assays (CPBA), radio-immunoassay (RIA), enzyme-linked immunoassay (ELISA), high-performance liquid chromatography (HPLC), liquid chromatography coupled with mass spectrometry (LC/MS), and random access automated assay (RAAA) based on chemiluminescence assay technology. Conventional techniques for vitamin D analysis, based on immunoassay or LC/UV, often lack adequate sensitivity, specificity, and speed; thus, interest in UHPLC/MS methods is growing. An advantage of UHPLC/MS technology is the ability to differentiate between 25(OH)D₂ and 25(OH)D₃ which is particularly useful when monitoring the vitamin D levels of patients being treated with vitamin D₂.

Experimental Conditions

Target Analytes: 25-Hydroxyvitamin D₂ and D₃

Sample Preparation Conditions

Human serum controls and patient unknown samples were obtained. 150 μ L serum was taken and 50 μ L internal standard, 25-Hydroxyvitamin D₃-d₆, added and vortex. 150 μ L 0.2 M ZnSo₄ was added and again vortex. Finally, 750 μ L Hexane was added to the mixture and centrifuged at 8000 RPM for 7 min. The top layer, organic phase, was removed and blown down under nitrogen and reconstituted in 100 μ L MeOH/H₂O and analyzed by HPLC/SQ MS.

Liquid Chromatography Conditions

Pump Type:	PerkinElmer® Flexar™ FX-10		
Column:	PerkinElmer Brownlee™ HRes Analytical DB C18 column (2.1 mm x 50 mm, 1.9 μ m)		
Mobile Phase:	A: water containing 2 mM Ammonium Acetate and 0.1% formic acid B: methanol containing 2 mM Ammonium Acetate and 0.1% formic acid		
Flow Rate:	0.3 mL/min		
Injection Volume:	8 μ L in micro liter pickup mode		
Isocratic			
Conditions:	Time (min)	%A	%B
	0	7	93
	6	7	93

Mass Spectrometer Conditions

Ionization:	Ultraspray™ ESI – Positive mode
The [M+H] ⁺ ions of each of the analytes were monitored:	
Time Period 1: (0-6 min) SIM ions 401.4, 407.4, 413.4 were monitored for 25-Hydroxyvitamin D ₃ , 25-Hydroxyvitamin D ₃ -d ₆ and 25-Hydroxyvitamin D ₂ respectively; dwell time of 150 ms each	
Capillary Exit Voltage:	45 V

Results

UHPLC/SQ MS allows for increased specificity for detection as compared to competitive protein binding assays (CPBA), radio-immunoassay (RIA), enzyme-linked immunoassay (ELISA), high-performance liquid chromatography (HPLC) as it can monitor both D₂ and D₃ levels separately as opposed to total vitamin D. This is important especially for patients being treated with vitamin D₂.

Measurement of both 25-hydroxyvitamin D₂ and D₃ is possible using the Flexar SQ 300 MS with a simple protein precipitation/ LLE method. The conditions used here for routine vitamin D testing by UHPLC/SQ MS resulted in highly symmetric peaks with a run time of 6 min which is much faster than competing techniques. We were able to detect and quantify patient samples below 4 ng/mL.

According to current industry definitions, severe deficiency can be defined as <6 ng/mL, deficiency as 16 ng/mL, insufficiency as <20 ng/mL and as normal >20 ng/mL.¹

Therefore, the Flexar SQ 300 MS is fully capable of detecting and quantifying within the clinical significant range for vitamin D.

¹Mosekilde L et al, *Ugeskr Læger* 167/11, 2005, 29-33.




Figure 3. Patient sample with separation and detection of 25-hydroxyvitamin D₂ (blue trace), 25-hydroxyvitamin D₃ (red trace) and 25-hydroxyvitamin D₃-d₆ (purple trace).




Figure 4. Standard injection of 25-hydroxyvitamin D₃-d₆ at 3 ng/mL.




Figure 5. Calibration curve for 25-hydroxyvitamin D₃ concentration range from blank to 73 ng/mL.